CLAIMS

1. A method of treating Alzheimer's Disease comprising administering orally to a human subject a daily dose of 180 mg of 1',3'-dihydro-2H-spiro[imidazo-[1,2a]pyridine-3,2'-inden]-2-one (AD101).
2. A method of treating Alzheimer's Disease comprising administering orally to a human subject a daily dose of 180 mg of AD101 and a dose of donepezil hydrochloride.
3. The method of claim 1 or 2, where the subject is already treated with donepezil hydrochloride in a stable dose prior to the first administered dose of AD101.
4. The method of claim 2 or 3, wherein donepezil hydrochloride is administered to the subject at a daily dose of 5 mg, 10 mg or 23 mg.
5. The method of any one of claims 2-4, wherein donepezil hydrochloride is administered as a film-coated tablet or an orally disintegrating tablet.
6. The method of any one of claims 2-4, wherein donepezil hydrochloride is administered via a once-per-week transdermal patch.
7. The method of any one of claims 2-6, wherein donepezil hydrochloride is administered at an initial daily dose of 10 mg which is increased to a maintenance daily dose of 23 mg donepezil hydrochloride.
8. The method of any one of claims 1-7, wherein AD101 is administered as 3 tablets each comprising 60 mg of AD101, as 2 tablets each comprising 90 mg of AD101 or as a single tablet comprising 180 mg AD101.
9. The method of any one of claims 1-8, wherein donepezil hydrochloride is administered once-daily (QD).
10. The method of any one of claims 1-9, wherein the subject is treated with one or more additional therapeutic agents.
11. The method of any one of claims 2-10, wherein the co-administration of AD101 and donepezil hydrochloride has an additional beneficial effect on the condition of the treated subject relative to the administration of AD101 or donepezil hydrochloride alone.
12. The method of any one of claims 1-11, wherein the subject is also co-administered memantine hydrochloride.

13. The method of claim 12, where the subject is already treated with memantine hydrochloride in a stable dose prior to the first administered dose of AD101.
14. The method of claim 12 or 13, wherein memantine hydrochloride is administered orally to the subject at a daily dose of about 5 mg to about 30 mg.
15. The method of claim 14, wherein memantine hydrochloride is administered orally to the subject at a daily dose of 5 mg or 20 mg.
16. The method of any one of claims 12-14, wherein memantine hydrochloride is administered orally to the subject at a daily dose of 7 mg, 14 mg or 28 mg.
17. The method of any one of claims 12-16, wherein the co-administration of AD101, memantine hydrochloride and donepezil hydrochloride has an additional beneficial effect on the condition of the treated subject relative to the administration of AD101, memantine hydrochloride or donepezil hydrochloride alone.
18. The method of any one of claims 1-16, wherein the subject demonstrates an improvement in cognition or overall ability to function in their everyday activities (global function) following treatment.
19. The method of any one of claims 1-18, wherein the human subject with an has a Mini-Mental State Examination (MMSE) score of 10 to 24 at the onset of treatment with AD101.
20. The method of any one of claims 1-19, wherein the subject exhibits dementia of the Alzheimer's type.
21. The method of any one of claims 1-20, wherein the 180 mg of AD101 is comprised in one or more oral pharmaceutical preparations together with one or more excipients and/or carriers.
22. The method of claim 21, wherein the oral pharmaceutical preparation is a tablet.